Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 24, 2026

Generation of Monocyte-Derived Dendritic Cells with Differing Sialylated Phenotypes
13:36

Generation of Monocyte-Derived Dendritic Cells with Differing Sialylated Phenotypes

Published on: October 20, 2023

Comprehensive Profiling Reveals Sialyl-Tn Upregulation and Prognostic Value in Prostate Cancer.

Kirsty Hodgson1, Libby Blencoe1, Erin Smith1

  • 1Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK.

Pathology International
|June 23, 2026
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis.

British journal of cancer·2026
Same author

The glycobiology of prostate cancer: an update.

Oncogene·2026
Same author

Bedaquiline inhibits the ATP synthase leak channel and prevents glutamate-induced neuronal death.

Biophysical reports·2026
Same author

Comprehensive profiling reveals Sialyl-Tn upregulation and prognostic value in prostate cancer.

bioRxiv : the preprint server for biology·2026
Same author

Low muscle mass in interstitial lung disease: a systematic review and meta-analysis of prevalence and clinical associations.

BMC pulmonary medicine·2026
Same author

Examining the Impact of Side-Chain Chirality on Conformation of a Helical Poly(3‑(<i>S</i>‑1-ethylhexyl)esterfuran).

Macromolecules·2026

Sialyl-Tn antigen (sTn) is expressed in prostate tumors and linked to poorer survival. This study identifies sTn as a potential biomarker and therapeutic target for advanced prostate cancer.

Area of Science:

  • Oncology
  • Glycobiology
  • Cancer Research

Background:

  • Aberrant glycosylation is a key feature of prostate cancer, influencing disease progression.
  • The sialyl-Tn antigen (sTn), a specific glycan structure, has roles in various cancers but is understudied in prostate cancer.
  • There is a critical need for novel therapeutic strategies for advanced prostate cancer.

Purpose of the Study:

  • To investigate the expression and clinical significance of the sialyl-Tn antigen (sTn) in prostate cancer.
  • To evaluate sTn as a potential prognostic biomarker and therapeutic target in prostate cancer, including advanced and metastatic forms.

Main Methods:

  • Utilized a novel anti-sTn antibody (L2A5) for comprehensive monitoring of sTn expression.
  • Analyzed sTn levels in clinical prostate tissues (normal, benign, primary, metastatic castration-resistant prostate cancer [CRPC]) and patient-derived xenograft (PDX) models.

Related Experiment Videos

Last Updated: Jun 24, 2026

Generation of Monocyte-Derived Dendritic Cells with Differing Sialylated Phenotypes
13:36

Generation of Monocyte-Derived Dendritic Cells with Differing Sialylated Phenotypes

Published on: October 20, 2023

  • Correlated sTn expression levels with patient survival data and androgen regulation.

    • Main Results:

    • sTn expression was low in normal prostate tissues but detected in 44% of prostate tumors.
    • High sTn levels in prostate cancer patients correlated significantly with poorer survival outcomes.
    • sTn was expressed in 37.5% of metastatic therapy-resistant prostate tumors and nearly half of PDX models, showing broad androgen regulation.

    Conclusions:

    • sTn is a promising prognostic biomarker for prostate cancer, particularly for predicting survival.
    • sTn represents a potential therapeutic target for developing precision therapies for advanced prostate cancer.
    • Further research into sTn-targeted therapies is warranted for improved treatment of advanced prostate cancer.